Shots:
- Lupin has entered into an exclusive licensing agreement with Valorum Biologics for Armlupeg, a biosimilar version of Neulasta (pegfilgrastim)
- As per the deal, Valorum will be responsible for the commercialization and distribution of Armlupeg in the US, while Lupin will handle manufacturing & supply of the product
- In return, Lupin will receive an upfront license fee & royalty payment on net sales, though financial terms remain undisclosed
Ref: Lupin | Image: Lupin & Valorum | Press Release
Related News: Lupin Collaborates with Sandoz to Commercialize Ranibizumab Biosimilar
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
